Classys

Classys, founded in 2007 as a maker of medical devices for aesthetic use, listed on KOSDAQ in 2017 via a SPAC merger and runs the clinic-focused Classys brand alongside Cluederm for aesthetic salons and home beauty device and cosmetics brands.

Its lineup spans the high-intensity focused ultrasound (HIFU) devices Shurink and Shurink Universe (exported as Ultraformer MPT), the monopolar radiofrequency device Volnewmer (Everesse in the United States), the microneedle radiofrequency device Quadessy and the laser device reepot, with consumables such as cartridges and tips accruing as the installed base and procedure volumes grow.

That razor-and-blade structure is the backbone of profitability, and on the company's account the global cumulative installed base rose to about 48,000 units as of the end of June 2026.

That said, a DB Financial Investment report in August 2026 put the consumables share of total 2Q26 revenue at 37.2%, down 5.1 percentage points from a year earlier. The regional mix has tilted further offshore: press tallies put 2Q26 overseas revenue at 68.1 billion won, up 27.6% year on year.

Distribution is also being reshaped.

In Brazil the acquisition of JL Health, parent of local distributor MedSystems, closed on 5 March 2026, moving the market to direct sales; the company said Japan shifted fully to direct sales from August 2026; and North America is covered through distributor Cartessa across the United States and Canada.

The product range widened through the Ilooda merger, and a Hana Securities report in February 2026 put Ilooda's 2025 revenue at 60 billion won, or 18% of the group total.

Competition is tightening as domestic peers such as Wontech, Jeisys Medical and Pharma Research are joined by APR, which built its base in home beauty devices and is preparing to enter the clinic market with energy-based aesthetic devices and skin boosters. The largest shareholder is Bain Capital, which acquired the controlling stake in 2022.

The annual trend has been clearly upward.

Revenue rose from 141.8 billion won in 2022 to 180.1 billion won in 2023, 242.9 billion won in 2024 and 336.8 billion won in 2025, roughly 2.4 times in three years, while operating profit climbed from 68.9 billion won to 170.6 billion won and the operating margin edged up from 48.6% to 49.8%, 50.4% and 50.7%.

Net profit attributable to owners was 131.9 billion won in 2025 and operating cash flow reached 163.9 billion won, about 96% of operating profit, while the debt-to-equity ratio fell from 44.4% in 2022 to 27.7% in 2025. The issue lies in the margin path of the past five quarters.

From 83.3 billion won of revenue and 43.0 billion won of operating profit in 2Q25 (51.6% margin), 83.0 billion and 37.6 billion in 3Q25 (45.3%) and 93.4 billion and 51.2 billion in 4Q25 (54.8%), the company moved to 87.2 billion and 37.2 billion in 1Q26 (42.7%) and 105.5 billion and 43.9 billion in 2Q26 (41.6%): quarterly revenue topped 100 billion won for the first time, but the margin settled in the low 40% range.

Revenue rose 26.7% year on year in 2Q26 while operating profit grew only 2.2%, a numerical illustration that the character of growth has changed.

Cited drivers include the consolidation of the Brazilian distributor, which brings distribution-stage revenue and costs onto the books, a lower consumables mix and a first-half concentration of expenses.

Yuanta Securities noted that costs for KIMES-related user events, home beauty device marketing, China entry consulting fees and post-merger integration advisory for MedSystems were concentrated in 1Q26, while Hana Securities explained that a reversal of Brazil-related bad-debt provisions added to profit in 4Q25.

A DB Financial Investment report in August 2026 tallied 2Q26 domestic equipment revenue at 7.7 billion won, down 39.4%, and consumables at 12.8 billion won, down 15.1%.

Summing the four quarters from 3Q25 to 2Q26 gives revenue of 369.1 billion won and operating profit of 170.0 billion won for a margin of about 46%, with net profit attributable to owners totalling 137.6 billion won.

Notably, 2Q26 net profit attributable to owners of 28.4 billion won sat well below the same quarter's operating profit of 43.9 billion won, and the detailed reasons are a matter to verify in the quarterly report footnotes.

Energy-based aesthetic devices (EBD) sit at the high-margin end of manufacturing because equipment placements generate recurring consumables revenue, and Korean players have used that model to lift export shares quickly.

On end-market size, the United States is the largest at 13.7 billion dollars, Europe ranks second at an estimated 8 trillion to 10 trillion won, and China's aesthetic medical market was reported at 307.2 billion yuan (about 61 trillion won) for 2024, so the very act of shifting the stage from Brazil and Thailand, where Classys has been strong, to Western markets and China is itself an industry growth axis.

Domestic growth is comparatively moderate, with one market research house estimating the Korean aesthetic device market rising from 567.75 million dollars in 2026 to 838.63 million dollars in 2031, a compound annual rate of 8.11%.

Lifting devices, already widely penetrated at home, depend on replacement cycles and clinic capital spending, while inbound medical tourism provides a cushion.

On competition, alongside incumbents such as Wontech and Jeisys Medical, APR, which grew from cosmetics and home devices, is preparing to enter with clinic-grade EBD and skin boosters, pointing to tougher domestic equipment and promotion competition.

On the valuation cycle, Hana Securities argued in a January 2026 report that the aesthetic medical sector's weak 2025 returns stemmed from multiple contraction rather than an earnings slowdown.

In other words the sector has passed through a phase of growing profits and shrinking multiples, and within it Classys stands out for its revenue scale and the breadth of its export diversification.

The most firmly established fact is the reset of targets.

The company disclosed on 12 August 2026 that it was cutting the full-year revenue target of 490 billion won set in February 2026 to 445 billion won, and DB Financial Investment summarised that the consolidated revenue outlook range was moved from 470-510 billion won to 430-460 billion won, with the Brazil assumption trimmed from 50-70 billion won to the 40 billion won range.

Domestic softness and the pace of Quadessy sales at home are cited as the reasons, and press reports note that Quadessy resumed full shipments from April 2026 after development work to improve usability. The overseas plan, by contrast, is being maintained.

Kyobo Securities said in a July 2026 report that the annual target of 300 Everesse units for the United States and the second-half China approval goal for Volnewmer were intact, while Samsung Securities in an April 2026 report flagged a September 2026 China approval for Volnewmer with initial shipments around year-end, plus United States and China approvals for Shurink in 2027, as medium-term catalysts.

The company has said that once China approvals are complete it aims to secure roughly 100 billion won of its 1 billion dollar revenue goal for 2030 from that market.

Domestically, management has pointed to stronger package promotions to restore leadership, with the shift to direct sales in Japan as another second-half watch item.

In sum, the second half of 2026 tests both the process of filling a lowered target and whether the two new growth axes, direct sales in Brazil and China approval, translate into actual revenue.